Resources Newsletter Advertise Sign in

Subscribe Find a Doctor

Sat, Oct 3, 2026

Latest

RESEARCH

New StudiesWhat was published and what it means Clinical TrialsWhat is enrolling, what is reading out Evidence CheckWhere the data stands on a claim Research TranslationFrom the lab to the clinic Biology of AgingHallmarks, senescence, epigenetics

Caloric restriction improves a composite aging-biomarker index

Caloric restriction improves a composite aging-biomarker index

By longevitydocs™ editors

Menopause leaves a molecular signature linked to brain aging

Menopause leaves a molecular signature linked to brain aging

By longevitydocs™ editors

Editorial standards

CLINICAL PRACTICE

Practice ModelsHow longevity care is structured and delivered Clinical CasesReal patients, real clinical decisions Guidelines & StandardsConsensus statements and best practice Field ReportsCLDs on what works in their practice

Ferritin below 30 is the new line

Guidelines & Standards

Ferritin below 30 is the new line

By longevitydocs™ editors

Where can I find a longevity doctor?

Practice Models

Where can I find a longevity doctor?

By David Luu, MD

Editorial standards

THERAPEUTICS

Metabolic HealthGLP-1s, insulin, cardiometabolic risk Hormones & Midlife CareHRT, testosterone, menopause Supplements & PeptidesWhat is proven, what is not Regenerative MedicineStem cells, exosomes, PRP Skin & Aesthetic LongevityLongevity dermatology and aesthetics

Tirzepatide earns its first outcomes label

Metabolic Health

Tirzepatide earns its first outcomes label

By longevitydocs™ editors

The Lp(a) drug moved the number, not the outcome

Metabolic Health

The Lp(a) drug moved the number, not the outcome

By longevitydocs™ editors

Editorial standards

DIAGNOSTICS

BiomarkersBlood panels, ApoB, inflammation Biological AgeEpigenetic clocks and how to read them ImagingFull-body MRI, CAC scores, DEXA GenomicsPolygenic risk, pharmacogenomics Screening & PreventionEarly detection and risk reduction

Alzheimer’s blood tests are for symptomatic patients, not screening

Screening & Prevention

Alzheimer’s blood tests are for symptomatic patients, not screening

By longevitydocs™ editors

Which longevity data is worth acting on?

Which longevity data is worth acting on?

By David Luu, MD

Editorial standards

TECHNOLOGY

AI in MedicineClinical tools, decision support Wearables & Remote MonitoringCGMs, rings, continuous data Devices & At-Home CareHome diagnostics and hardware Digital Health InfrastructurePlatforms, records, telehealth

Lab-grade breath testing goes self-serve

Devices & At-Home Care

Lab-grade breath testing goes self-serve

By longevitydocs™ editors

Your ring now carries your chart

Wearables & Remote Monitoring

Your ring now carries your chart

By longevitydocs™ editors

Editorial standards

BUSINESS

Clinics & PracticesModels, pricing, operations Care DeliveryHow providers and health systems offer longevity care Pharma & BiotechPipelines, launches, trials Deals & FundingRaises, M&A, partnerships

System raises $20M to own the peptide supply chain

Deals & Funding

System raises $20M to own the peptide supply chain

By longevitydocs™ editors

Bryan Johnson’s Immortals Concierge: from $75k to $1M

Bryan Johnson’s Immortals Concierge: from $75k to $1M

By longevitydocs™ editors

Editorial standards

POLICY

Regulation & EnforcementFDA actions, compounding, warnings Payment & ReimbursementCoverage, codes, payers Licensure & StandardsScope of practice, credentialing Global PolicyHow other countries regulate longevity care

FDA puts a major GLP-1 compounder on notice

Regulation & Enforcement

FDA puts a major GLP-1 compounder on notice

By longevitydocs™ editors

$16.4 trillion: the economic case for prevention

$16.4 trillion: the economic case for prevention

By longevitydocs™ editors

Editorial standards

VOICES

OpinionPhysicians argue a position InterviewsConversations with the people shaping the field DebatesTwo physicians, one question From the EditorsNotes from the longevitydocs™ editors

What People Get Wrong About Longevity Medicine

What People Get Wrong About Longevity Medicine

By David Luu, MD

10 learnings from longevitydocs Cannes 2026

From the Editors

10 learnings from longevitydocs Cannes 2026

By David Luu, MD

Editorial standards

Diagnostics

Biomarkers, imaging and the tests entering the longevity visit.

All Biomarkers Biological Age Imaging Genomics Screening & Prevention

Diagnostics · Biomarkers

Which longevity data is worth acting on?

For years, we said we didn’t have enough data for precision medicine. Now we have more than we can interpret.

By David Luu, MDSep 27, 2026

Which longevity data is worth acting on?

Diagnostics · Biomarkers

The Biomarker Gold Rush

Function Health raised $298M, dropped membership to $365/year, and launched Medical Intelligence Lab: an AI engine merging 160+ biomarkers, full-body imaging, wearables, and medical records into personalized protocols.

By David Luu, MDNov 23, 2025

The Biomarker Gold Rush

The Sunday edition.

The week in longevity medicine, every Sunday.

Free, delivered by Substack. Unsubscribe any time.

Embed not loading? Subscribe on Substack

Find a Doctor

All Research New Studies Clinical Trials Evidence Check Research Translation Biology of Aging

All Clinical Practice Practice Models Clinical Cases Guidelines & Standards Field Reports

All Therapeutics Metabolic Health Hormones & Midlife Care Supplements & Peptides Regenerative Medicine Skin & Aesthetic Longevity

All Diagnostics Biomarkers Biological Age Imaging Genomics Screening & Prevention

All Technology AI in Medicine Wearables & Remote Monitoring Devices & At-Home Care Digital Health Infrastructure

All Business Clinics & Practices Care Delivery Pharma & Biotech Deals & Funding

All Policy Regulation & Enforcement Payment & Reimbursement Licensure & Standards Global Policy

All Voices Opinion Interviews Debates From the Editors

Subscribe Resources Newsletter Advertise Sign in